Literature DB >> 24501385

Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor.

Andreas Kyvernitakis1, Elias Jabbour, Harrys A Torres.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24501385      PMCID: PMC4184347          DOI: 10.1093/cid/ciu070

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.

Authors:  Natalie Brulotte; Hejin Hahn; Maximilian Lee
Journal:  Dig Dis Sci       Date:  2013-10-10       Impact factor: 3.199

2.  Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man.

Authors:  Edward R Cachay
Journal:  Clin Infect Dis       Date:  2012-09-21       Impact factor: 9.079

3.  Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus.

Authors:  Sandra Beinhardt; Karoline Rutter; Albert Friedrich Stättermayer; Peter Ferenci
Journal:  Clin Infect Dis       Date:  2012-09-28       Impact factor: 9.079

4.  Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

Authors:  Annette Bruchfeld; Karin Lindahl; Robert Schvarcz; Lars Ståhle
Journal:  Ther Drug Monit       Date:  2002-12       Impact factor: 3.681

5.  Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.

Authors:  Stefan Mauss; Dietrich Hueppe; Ulrich Alshuth
Journal:  Hepatology       Date:  2013-11-11       Impact factor: 17.425

6.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.